Adverum Biotechnologies, Inc.

Introduction

This page provides a comprehensive analysis of the known insider trading history of Leone D Patterson. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Leone D Patterson has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
EVP, Chief Bus & Fin Officer 0
US:TNYA / Tenaya Therapeutics, Inc. Chief Fin. and Bus. Officer 95,755
US:NKTX / Nkarta, Inc. Director 16,511
US:ADVM / Adverum Biotechnologies, Inc. President and CFO 240,000
US:DDXS / Diadexus, Inc. Chief Financial Officer 700,000
US:TSPT / Vice President, CFO 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Leone D Patterson. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ADVM / Adverum Biotechnologies, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ADVM / Adverum Biotechnologies, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ADVM / Adverum Biotechnologies, Inc. Insider Trades
Insider Sales ADVM / Adverum Biotechnologies, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ADVM / Adverum Biotechnologies, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2021-02-09 ADVM PATTERSON LEONE D 12,471 14.1000 1,247 141.0000 175,841 352 1.5000 -173,970 -98.94
2021-02-09 ADVM PATTERSON LEONE D 62 14.1393 6 141.3930 877
2020-06-16 ADVM PATTERSON LEONE D 13,171 24.6800 1,317 246.8000 325,060

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ADVM / Adverum Biotechnologies, Inc. Insider Trades
Insider Purchases NKTX / Nkarta, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ADVM / Adverum Biotechnologies, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NKTX / Nkarta, Inc. Insider Trades
Insider Sales NKTX / Nkarta, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ADVM / Adverum Biotechnologies, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NKTX / Nkarta, Inc. Insider Trades
Insider Purchases TNYA / Tenaya Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ADVM / Adverum Biotechnologies, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TNYA / Tenaya Therapeutics, Inc. Insider Trades
Insider Sales TNYA / Tenaya Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ADVM / Adverum Biotechnologies, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2024-02-16 TNYA PATTERSON LEONE D 5,201 5.8600 5,201 5.8600 30,478 360 0.8971 -25,811 -84.69
2023-08-16 TNYA PATTERSON LEONE D 4,452 3.8100 4,452 3.8100 16,962

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TNYA / Tenaya Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Leone D Patterson as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-09-03 3 ZYME Zymeworks Inc.
No securities are beneficially owned
0
2024-02-27 2024-02-23 4 TNYA Tenaya Therapeutics, Inc.
Common Stock
A - Award 35,000 95,755 57.61
2024-02-16 2024-02-16 4 TNYA Tenaya Therapeutics, Inc.
Common Stock
S - Sale -5,201 60,755 -7.89 5.86 -30,478 356,024
2023-08-18 2023-08-16 4 TNYA Tenaya Therapeutics, Inc.
Common Stock
S - Sale -4,452 64,542 -6.45 3.81 -16,962 245,905
2023-02-17 2023-02-15 4 TNYA Tenaya Therapeutics, Inc.
Common Stock
A - Award 35,000 67,000 109.38
2023-02-17 2023-02-15 4 TNYA Tenaya Therapeutics, Inc.
Common Stock
A - Award 30,000 32,000 1,500.00
2022-02-17 2022-02-15 4 TNYA Tenaya Therapeutics, Inc.
Stock Option (Right to buy)
A - Award 66,000 66,000
2021-06-15 2021-06-13 4 NKTX Nkarta, Inc.
Stock Option (right to buy)
A - Award 16,511 16,511
2021-02-18 2021-02-16 4 ADVM Adverum Biotechnologies, Inc.
Stock Option (Right to Buy)
A - Award 240,000 240,000
2021-02-11 2021-02-09 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
S - Sale -62 97,955 -0.06 14.14 -877 1,385,015
2021-02-11 2021-02-09 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
S - Sale -12,471 98,017 -11.29 14.10 -175,841 1,382,040
2020-07-13 2020-07-09 4 NKTX Nkarta, Inc.
Stock Option (right to buy)
A - Award 18,300 18,300
2020-07-13 2020-07-09 4 NKTX Nkarta, Inc.
Stock Option (right to buy)
A - Award 10,700 10,700
2020-06-17 2020-06-16 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
S - Sale -13,171 110,488 -10.65 24.68 -325,060 2,726,844
2020-05-08 2020-05-06 4 ADVM Adverum Biotechnologies, Inc.
Stock Option (Right to Buy)
M - Exercise -20,000 155,576 -11.39
2020-05-08 2020-05-06 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
S - Sale X -20,000 123,659 -13.92 20.02 -400,400 2,475,653
2020-05-08 2020-05-06 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
M - Exercise 20,000 143,659 16.17 3.44 68,800 494,187
2020-05-08 2020-02-09 4/A ADVM Adverum Biotechnologies, Inc.
Common Stock
F - Taxes -10,985 139,235 -7.31 10.24 -112,486 1,425,766
2020-03-25 2020-03-20 4 ADVM Adverum Biotechnologies, Inc.
Stock Option (Right to Buy)
M - Exercise -24,424 175,576 -12.21
2020-03-25 2020-03-20 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
S - Sale X -39,526 123,429 -24.26 10.17 -401,908 1,255,051
2020-03-25 2020-03-20 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
M - Exercise 24,424 162,955 17.63 3.44 84,019 560,565
2020-03-18 2020-03-17 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
S - Sale X -474 138,531 -0.34 10.02 -4,749 1,388,011
2020-02-21 2020-02-20 4 ADVM Adverum Biotechnologies, Inc.
Stock Option (Right to Buy)
A - Award 300,000 300,000
2020-02-10 2020-02-09 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
F - Taxes -11,215 139,005 -7.47 10.24 -114,842 1,423,411
2020-02-10 2019-06-15 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
F - Taxes -35,282 190,220 -15.65 10.82 -381,751 2,058,180
2020-02-10 2019-06-15 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
F - Taxes -8,570 225,502 -3.66 10.82 -92,727 2,439,932
2020-02-10 2019-02-09 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
F - Taxes -8,176 234,072 -3.38 3.33 -27,226 779,460
2020-02-10 2018-06-15 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
F - Taxes -8,645 242,248 -3.45 5.55 -47,980 1,344,476
2020-02-10 2018-02-09 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
F - Taxes -8,208 162,397 -4.81 7.05 -57,866 1,144,899
2020-02-10 2017-06-15 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
F - Taxes -9,395 170,605 -5.22 2.70 -25,366 460,634
2020-02-10 2019-12-23 4/A ADVM Adverum Biotechnologies, Inc.
Common Stock
S - Sale X -40,000 150,220 -21.03 10.72 -428,800 1,610,358
2019-12-26 2019-12-23 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
S - Sale X -40,000 228,496 -14.90 10.72 -428,800 2,449,477
2019-02-19 2019-02-14 4 ADVM Adverum Biotechnologies, Inc.
Stock Option (Right to Buy)
A - Award 800,000 800,000
2018-10-22 2018-10-18 4 ADVM Adverum Biotechnologies, Inc.
Stock Option (Right to Buy)
A - Award 150,000 150,000
2018-06-18 2018-06-15 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
A - Award 88,496 268,496 49.16
2018-02-20 2018-02-15 4 ADVM Adverum Biotechnologies, Inc.
Stock Option (Right to Buy)
A - Award 160,000 160,000
2017-02-13 2017-02-09 4 ADVM Adverum Biotechnologies, Inc.
Stock Option (Right to Buy)
A - Award 116,000 116,000
2017-02-13 2017-02-09 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
A - Award 80,000 180,000 80.00
2016-06-16 2016-06-15 4 ADVM Adverum Biotechnologies, Inc.
Stock Option (Right to Buy)
A - Award 200,000 200,000
2016-06-16 2016-06-15 4 ADVM Adverum Biotechnologies, Inc.
Common Stock
A - Award 100,000 100,000
2015-03-24 2015-03-20 4 DDXS diaDexus, Inc.
Stock Option (Right to Buy)
A - Award 700,000 700,000
2015-03-24 3 DDXS diaDexus, Inc.
No Securities Owned.
0
2014-10-30 2014-10-30 4 TSPT Transcept Pharmaceuticals Inc
Stock Option (right to buy)
D - Sale to Issuer -9,583 0 -100.00
2014-10-30 2014-10-30 4 TSPT Transcept Pharmaceuticals Inc
Stock Option (right to buy)
D - Sale to Issuer -6,666 0 -100.00
2014-10-30 2014-10-30 4 TSPT Transcept Pharmaceuticals Inc
Stock Option (right to buy)
D - Sale to Issuer -7,500 0 -100.00
2014-10-30 2014-10-30 4 TSPT Transcept Pharmaceuticals Inc
Common Stock
A - Award 4,161 4,161 21.59 89,828 89,828
2013-07-18 2013-07-15 4 TSPT Transcept Pharmaceuticals Inc
Common Stock Option (right to buy)
A - Award 115,000 115,000
2013-01-08 2013-01-07 4 TSPT Transcept Pharmaceuticals Inc
Common Stock Option (right to buy)
A - Award 80,000 80,000
2012-06-26 2012-06-25 4 TSPT Transcept Pharmaceuticals Inc
Employee Stock Option (right to buy)
A - Award 90,000 90,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)